आईएसएसएन: 2329-6917
Toby A Eyre, Angela Hamblin and Anna Schuh
T cell ProLymphocytic Leukemia (T-PLL) is a rare lymphoid malignancy and is typified by its aggressive presentation and chemo-resistance. Given its rarity, haemato-oncologists are likely to manage only a handful of cases across their career and therefore making the diagnosis is the initial challenge. This diagnosis is critical, as recent data suggests that choosing specific treatment options, such as alemtuzumab, is important in improving outcomes.